Stockscreener 앱 받기
10.62
0.00%
0.00
시간 외 거래:
10.62
Drugs Made In America Acquisition Corp 주식(DMAA)의 최신 뉴스
DMAAR Rights Trade Flat Near All-Time Low as Investors Await Merger CatalystBearish Pattern Stocks - newsline.com
DMAA Hovers Near $10.62 as SPAC Consolidates Ahead of Potential CatalystFair Value Gap - newsline.com
US Retreat from Global Leadership Stirs Uncertainty Across AsiaFinancial Health Score - newsline.com
Drugs Made In America Acquisition II Corp. Right (DMIIR) Holds Flat at $0.08 as Rights Trading Remains DormantDip Buy Trade - newsline.com
DMII Holds Steady at $10.08: SPAC Trading in a Narrow RangeTICK Divergence - newsline.com
DMIIU Holds Steady at $10.12 as SPAC Unit Trades in Tight RangeFear Greed Extreme - newsline.com
DMIIR Rights Trading Slumps 9.09% to $0.08 – Micro-Cap Struggles for DirectionReversal Setup Alerts - newsline.com
SUNE Q2 2024 Earnings: EPS Surges Past Estimates Despite Heavy Losses; Stock Plummets 27%Fiscal Year Earnings - newsline.com
Grove Collaborative (GROV) Edges Higher as Shares Approach Resistance ZoneSMA Signal - newsline.com
Number of shareholders of Drugs Made In America Acquisition II Corp. – NASDAQ:DMIIR - TradingView
GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover - Reuters
Brand Engagement Network Inc. (BNAI) Q3 2025 Earnings: Narrowed Loss Surprises as Pre-Revenue Company Gains MomentumEarnings Growth Forecast - newsline.com
Broadcom, Micron, ARM Lead Chip Stock Decline After Disappointing Broadcom EarningsHigh Estimate Range - newsline.com
Free float of Drugs Made In America Acquisition Corp. – NASDAQ:DMAAR - TradingView
QDRO Acquisition Corp.: Performance & Quotes, QADR Stock Price on Nasdaq Exchange - marketscreener.com
Drugs Made In America Acquisition II Corp. appoints new CEO after sponsor repayment issue - Investing.com
Drugs Made In America Acquisition Corp. Rights (DMAAR) Edge Higher Amid Low-Price SpeculationVolume Climax - newsline.com
DeFi Development Corp. Warrant (DFDVW) Testing Support After 3.85% DeclineRatio Spread Trade - thelegaladvocate.com
VTAK Q1 2025 Earnings: Significant EPS Miss Amid Operational ChallengesEarnings Call Transcript - newsline.com
Shalibhadra Finance Targets Rs 500 Crore AUM on 22% Profit Growth in FY26Net Income Trends - thelegaladvocate.com
SQM Q2 2025 Earnings: Lithium Miner Posts $0.31 EPS as Shares Rise 2.17% Amid Market UncertaintyEarnings Weakness Phase - lwvtexas.org
Drugs Made In America Acquisition II Corp. Right (DMIIR) Drops 10% as Rights Trade Near Support at $0.08Volatility Breakout Picks - The Legal Advocate
Drugs Made In America Acquisition II Corp. Unit (DMIIU) Holds Steady Amid Extended ConsolidationVolatility Smirk - The Legal Advocate
Drugs Made In America Acquisition Corp. Rights (DMAAR) Slides 7.4% – Testing Key Support ZoneRip Sell Trade - newsline.com
NXRT Q1 2026 Earnings: Narrower-Than-Expected Loss, Stock Edges LowerBanking Earnings Report - thelegaladvocate.com
Drugs Made In America Acquisition II Corp. Right (DMIIR) Moves Up 8.91% at $0.09 – Right Securities See Renewed InterestGamma Squeeze - The Legal Advocate
Harvard Ave Acquisition (HAVA) Stock Holds Steady at $10.08 as Trading Remains FlatZero Lag EMA - The Legal Advocate
NXGL Q1 2026 Earnings: Larger-Than-Expected Loss Weighs on SharesEarnings Manipulation Risk - thelegaladvocate.com
Evolution Global Acquisition Corp Warrants (EVOXW) Surge 18.6% as Price Approaches Key ResistanceChaikin Flow - The Legal Advocate
DMII Holds Steady at $10.07 as SPAC Shares Track Trust ValueETF NAV Deviation - newsline.com
Eli Lilly and Company - Britannica
DMIIU Units Edge Lower by 0.44% as Price Holds Near $10.11 Amid Quiet TradingVWAP Breakout - thelegaladvocate.com
Drugs Made In America Acquisition II Corp. Unit (DMIIU) Holds Steady Near Trust Value Amid Low VolatilityInstitutional Sentiment - The Legal Advocate
DMIIR Rights Hover at $0.09 as Flat Trading Persists for Drugs Made In America Acquisition II Corp.Social Sentiment - The Legal Advocate
Huadi International Group (HUDI) Faces Steep Decline, Testing Key Support at $1.0Turnaround Stocks - thelegaladvocate.com
Drugs Made In America Acquisition II Corp. (DMII) Holds Steady Near Resistance: A Detailed AnalysisAdaptive Moving Average - The Legal Advocate
Drugs Made In America Acquisition Corp. Rights (DMAAR) Edges Higher: Analyzing the $0.12 LevelLiquidity Order Flow - newsline.com
SAGU_u|SAGU_u.NB|Price:10.090|Chg%:0.04 - TradingKey
PTACU|Patriot Acquisition Units (Proposed)|Price:9.950|Chg%:-0.01 - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
MMCAP International Inc. SPC's Drugs Made In America Acquisition II Corp(DMII) Holding History - GuruFocus
BioLife Solutions (BLFS) Faces Headwinds: Shares Decline 3.19% to $23.95ADD Alert - newsline.com
Trump-Xi Summit: The 3 Big Takeaways from Historic Meeting in BeijingReturn On Equity - The Legal Advocate
DMAA SEC FilingsDrugs Made In Amer Acqutn Corp 10-K, 10-Q, 8-K Forms - Stock Titan
BofA (BAC) Q1 2026 Earnings: $1.11 EPS Surges Past $1.02 EstimatesAdjusted Earnings Analysis - newsline.com
TradingKey - TradingKey
HEIGHTS CAPITAL MANAGEMENT, INC's Drugs Made In America Acquisition II Corp(DMIIU) Holding History - GuruFocus
Shutterstock, Inc. 8-K Filing: UK CMA Approves Merger with Getty Images Holdings, Inc - Minichart
Number of shareholders of Drugs Made In America Acquisition II Corp. – NASDAQ:DMII - TradingView
GUACU|Berto Acquisition II Units (Proposed)|Price:10.030|Chg%:-0.01 - TradingKey
DMAA Price Today: Drugs Made In America Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC
Drugs Made In America Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Drugs Made In America Acquisition Corp. Quarterly Earnings Report - Stock Titan
Drugs Made In America Acquisition II Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Drugs Made in America II (DMII) Q1 profit from trust interest amid going-concern risk - Stock Titan
Mizuho Financial Group reports 2,000,000 DMAA shares (DMAA) on 05/14/2026 - Stock Titan
Mercuria Capital Strategies, LLC's Drugs Made In America Acquisition Corp(DMAA) Holding History - GuruFocus
Number of shareholders of Drugs Made In America Acquisition Corp. – NASDAQ:DMAA - TradingView
'Drugs Made In America' SPAC Eyes $1B Deal With AI Platform - Law360
QRED|QuasarEdge Acquisition Units|Price:9.920| - TradingKey
Drugs Made In America Acquisition Corp (DMAA) and Power Analytics Global Corp Announce Definitive $1B AI Merger Agreement - Minichart
Drugs Made In America Acquisition Announces PAGC Merger Deal - TipRanks
Drugs Made In America Acquisition to Merge With Power Analytics Global in Deal Valued Up to $1 Billion - TradingView
DMAA (NASDAQ: DMAA) to combine with Power Analytics Global; $1.0B target valuation - Stock Titan
DMAA (NASDAQ: DMAA) sets $1.0B PAGC merger with 90/10 ownership split - Stock Titan
Leadership Compensation Aligned With Future Business Combination - TipRanks
0.10%
0.75%
자본화:
|
볼륨(24시간):